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Gemcitabine has been reported to be a potent radiosensitiser in human pancreatic cell lines. This study was conducted to evaluate
the efficacy and toxicity of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. In all, 42 patients with
pancreatic cancer that was unresectable but confined to the pancreatic region were treated with external-beam radiation (50.4Gy in
28 fractions over 5.5 weeks) and weekly gemcitabine (250mgm
 2, 30-min infusion). Maintenance gemcitabine (1000mgm
 2 weekly
 3 every 4 weeks) was initiated 1 month after the completion of the chemoradiotherapy and continued until disease progression or
unacceptable toxicity. Of the 42 patients, 38 (90%) completed the scheduled course of chemoradiotherapy. The major toxicity was
leucopenia and anorexia. There was one death attributed to duodenal bleeding and sepsis. The median survival time was 9.5 months
and the 1-year survival rate was 28%. The median progression-free survival time was 4.4 months. In 35 patients with documented
disease progression at the time of analysis, 34 (97%) showed distant metastasis as the cause of the initial disease progression. The
chemoradiotherapy used in this study has a moderate activity against locally advanced pancreatic cancer and an acceptable toxicity
profile. Future investigations for treatment with more systemic effects are warranted.
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Pancreatic cancer is the fourth leading cause of cancer death in the
United States and the fifth leading cause in Japan. The statistics
indicate a rapid increase in the number of deaths and the death
rate due to pancreatic cancer in Japan, but the precise reasons are
not clear, except for smoking. Pancreatic cancer in most patients is
surgically unresectable at the time of diagnosis because of the
difficulty of early detection of this disease. For patients with locally
advanced pancreatic cancer, chemoradiotherapy has been accepted
as standard treatment because the results of previous randomised
trials have indicated that concurrent external-beam radiation
therapy and 5-fluorouracil (5-FU) therapy results in a significantly
longer survival time than radiotherapy (Moertel et al, 1969;
Gastrointestinal Tumor Study Group, 1981) or chemotherapy
alone (Gastrointestinal Tumor Study Group, 1988). In attempts to
improve the efficacy of the treatment, numerous trials using
modified approaches of chemoradiotherapy have been conducted
(Chakravarthy and Abrams, 1997; Okada, 1999). However, there
has not yet been a regimen that has demonstrated superiority over
conventional chemoradiotherapy performed in randomised con-
trolled trials.
Gemcitabine is a novel deoxycytidine analog, which has
demonstrated significant clinical benefit and survival improve-
ment compared with 5-FU in patients with advanced pancreatic
cancer (Burris et al, 1997). Gemcitabine has also been shown to be
a potent radiosensitiser in human pancreatic and other solid
tumour cell lines (Lawrence et al, 1996; Shewach and Lawrence,
1996; van Putten et al, 2001), suggesting that the combination of
radiotherapy and gemcitabine may improve survival in patients
with locally advanced disease. A phase I trial that was conducted in
our hospital determined the recommended dose of weekly
gemcitabine for the phase II chemoradiotherapy trial to be
250mgm
 2 (Ikeda et al, 2002). We report our results of the phase
II study that was conducted to clarify the efficacy and toxicity of
concomitant chemoradiotherapy with gemcitabine in patients with
locally advanced pancreatic cancer.
PATIENTS AND METHODS
Patients eligible for this study had locally advanced pancreatic
cancer for which they had not received any anticancer treatment.
Each patient was required to meet the following eligibility criteria:
pathological proof of adenocarcinoma of the pancreas; an Eastern
Cooperative Oncology Group (ECOG) performance status of 0–2;
adequate bone marrow reserve (white blood cell count
X4000mm
3, platelet count X100000mm
3, haemoglobin level
X10gdl
 1); adequate renal function (normal serum creatinine
and blood urea nitrogen levels, and a creatinine clearance level
X60mgmin
 1); a serum aspartate aminotransferase (AST) level
o2.5 times upper normal limit (UNL); a serum alanine
aminotransferase (ALT) level o2.5 times UNL; and written
informed consent. Patients with obstructive jaundice were
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lrequired to have a serum total bilirubin level of less than
2.0mgdl
 1 after biliary drainage. Pretreatment staging included
ultrasonography and dynamic computed tomography (CT) scans
of both the abdomen and the chest. The possibility for resection of
the local tumour was assessed by dynamic CT and/or angiography.
Obstruction or bilateral invasion of the portal vein and/or tumour
encasement of the celiac or superior mesenteric arteries was
considered to be unresectable. Patients were excluded if they met
the following criteria: concomitant malignancy, pleural and/or
peritoneal effusion, active ulcer of the gastrointestinal tract, active
infection, severe heart disease, pregnant or lactating females, or
other serious medical conditions. The goal was set at 40 eligible
patients. This number of patients was planned using a design
based on the assumptions that the median survival time in
conventional chemoradiotherapy was 10 months, expected median
survival time was 14 months, type I error was 5% (one-tailed) and
statistical power was 70%.
Radiotherapy was delivered via a racetrack microtron (MM50,
Scanditronix, Upsala, Sweden) with a 25 MV X-rays. A total dose of
50.4Gy was delivered in 28 fractions over 5.5 weeks. All patients
had treatment planning, CT scans (X-vision, Toshiba, Tokyo) and
FOCUS (version 3.2.1, CMS, St Louis, MO, USA) was used as a
radiotherapy treatment planning system. Clinical target volume
(CTV) included the primary tumour, nodal involvement detected
by CT scan and regional draining and paraaortic lymph nodes,
which included the peripancreatic nodes, celiac and superior
mesenteric axes. Planning target volume was defined as CTV plus a
10-mm margin. Four field techniques (anterior, posterior and
opposed lateral fields) were used. Spinal cord dose was maintained
below 45Gy and X50% of liver was limited to p30Gy, X50% of
both kidneys were limited to p20Gy.
Gemcitabine at a dose of 250mgm
 2 was given intravenously
over 30min starting 2h before radiotherapy weekly for 6 weeks.
This schedule was based on an in vitro study which revealed that
gemcitabine induced its radiosensitising effect in cells within 2h
(Lawrence et al, 1997). Toxicity was assessed according to the
National Cancer Institute – Common Toxicity Criteria version 2.0.
When grade 3 haematological toxicity, serum creatinine of 1.5–2.0
times UNL, total bilirubin level of 3.0–5.0 times UNL, serum AST/
APT of 5.0–10 times UNL and/or grade 2 nonhaematological
toxicity (excluding nausea, vomiting, anorexia, fatigue, constipa-
tion, alopecia and dehydration) were observed, gemcitabine
administration was omitted and postponed to the next scheduled
treatment day. The radiotherapy was also suspended, and then
resumed when the toxicities recovered. In patients who experi-
enced the above adverse effects, dose reduction of gemcitabine to
200mgm
 2 was allowed in subsequent administrations. The
combined treatment was discontinued when grade 3 leucopenia
and/or neutropenia with high fever, grade 4 haematological
toxicities after dose reduction of gemcitabine, serum creatinine
of 42.0 times UNL, total bilirubin level of 45.0 times UNL, serum
AST/APT of 410 times UNL, grade 3 or 4 nonhaematological
toxicities (excluding nausea, vomiting, anorexia, fatigue, constipa-
tion, alopecia and dehydration), grade 4 vomiting, a total of 2
weeks of delay due to toxicity for any reason or tumour
progression were observed. At 1 month after the completion of
chemoradiotherapy, maintenance chemotherapy of gemcitabine at
a dose of 1000mgm
 2 was administered as a 30-min intravenous
infusion weekly for 3 weeks with 1-week rest until disease
progression or unacceptable toxicity. Follow-up CT was performed
within 1 week after the completion of chemoradiotherapy, and
thereafter every 2 months to evaluate tumour response according
to the WHO criteria (World Health Organization, 1979).
Progression-free and overall survival times were calculated from
the first day of treatment using the Kaplan–Meier method (Kaplan
and Meier, 1958). Serum CA 19-9 levels were measured monthly by
a radioimmunometric assay using the Centocor radioimmunoas-
say kit (Centocor, Inc., Malvern, PA, USA).
RESULTS
Patients and treatments
In all, 42 patients were enrolled in the study between July 2001 and
July 2002. Patient characteristics are listed in Table 1. A total of 38
patients (90%) received the full regimen of chemoradiotherapy,
and the remaining four patients (10%) discontinued the treatment
after 18.0–45.0Gy. The reasons for the treatment discontinuation
were elevated serum ALT of 410 times UNL (two patients),
duodenal bleeding (one), and patient’s refusal of treatment due to
general fatigue (one). After discontinuation of the chemora-
diotherapy, the two patients who showed the ALT elevation
suspected as gemcitabine-related toxicity received chemora-
diotherapy using 5-FU, and the other two patients underwent
only supportive care. Of 241, 30 (12%) planned gemcitabine
injections (0.7 injections per patient) were omitted owing to
adverse events including grade 3 or more leucopenia and/or
neutropenia, grade 2 fever, grade 2 skin rash and patient’s refusal
due to nausea, vomiting or fatigue. In three patients who showed
grade 4 leucopenia and/or neutropenia, the dose of gemcitabine
was modified in subsequent injections. Maintenance chemother-
apy was initiated in 23 of the 38 patients who completed the full
regimen of chemoradiotherapy. Of the remaining 15 patients,
seven showed deterioration of general condition due to disease
progression before initiating the chemotherapy, seven refused the
treatment due to appetite loss (4) or general fatigue (3) and one
transferred to another hospital (1).
Response and survival
Tumour response was determined in 40 patients. Two patients
were excluded from the protocol efficacy analysis because their
treatment was switched over to chemoradiotherapy using 5-FU
before the response evaluation due to the ALT elevation. Nine
patients (21%) achieved a partial response, 26 (62%) remained
stable and five (12%) showed progressive disease demonstrated by
the development of distant metastases. No patients could undergo
tumour resection even after the completion of chemoradiotherapy
because of infiltration of the adjacent large vessels. In 22 (76%) of
the 29 patients with a pretreatment serum CA19-9 (carbohydrate
antigen 19-9) level of 100Uml
 1 or greater, the level was reduced
more than 50% within 14 weeks after initiation of treatment.
Table 1 Patient characteristics
Number of patients 42
Gender
Male 19 (45%)
Female 23 (55%)
Age (years)
Median (range) 59 (43–73)
ECOG performance status
0 12 (29%)
1 30 (71%)
Tumour location
Head 21 (50%)
Body–tail 21 (50%)
CEA (ngml
 1)
Median (range) 11 (1.0–62.7)
CA19-9 (Uml
 1)
Median (range) 2775 (1–15620)
ECOG¼Eastern Cooperative Oncology Group; CEA¼carcinoembryonic antigen;
CA19-9¼carbohydrate antigen 19-9.
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time of analysis. The initial sites of disease progression are listed in
Table 2. The pattern of failure was distant metastases in 33 patients
(94%), local–regional recurrence in one patient (3%) and both in
one patient (3%). The median progression-free interval and the
median survival time were 4.4 and 9.5 months, respectively. The
overall 1- and 2-year survival rates were 28 and 23%, respectively
(Figure 1).
Toxicity
The acute toxicity is summarised in Table 3. The haematological
toxicity was relatively brief and reversible in most patients. Grade
3–4 leucopenia and neutropenia occurred in 22 (52%) and 14
(33%) of the patients, respectively. Grade 3 thrombocytopenia
occurred in one patient (2%) on the day after the chemoradiother-
apy completion. The patient, who showed grade 4 anaemia,
suffered catastrophic duodenal bleeding requiring embolisation
under angiography. She exhibited cholangitis and sepsis subse-
quently and died on day 63.
The most common nonhaematological toxicity was anorexia,
which was observed in 38 patients (90%). In total, 14 patients
(33%) required intravenous hyperalimentation. In all, 33 patients
(79%) complained of fatigue and one of them refused continuation
of the chemoradiotherapy. Nine patients (21%) experienced grade
3 nausea. Liver function abnormality was another major adverse
effect. Four patients (10%) showed grade 3 elevation of serum
transaminase levels. Two of them discontinued the treatments after
19.8 and 21.6Gy, respectively, due to serum ALT elevation of 10
times UNL according to the protocol criteria (maximum level: 452
and 435IUl
 1), although the serum ALT levels of both recovered
to the grade 1 levels 4 days after discontinuation of the treatment.
We suspected that the ALT elevation in these two patients was
gemcitabine-related toxicity because it was never reproduced after
their treatment was switched over to chemoradiotherapy using 5-
FU. One patient suffered unexpected acute abdominal pain
requiring morphine 2 months after the completion of the
chemoradiotherapy and was diagnosed with perforation of
pancreatic pseudocyst into the duodenum. This pain disappeared
completely by only medical management within 1 week. No
patients experienced any symptoms considered to be late toxicity
as of the time of analysis.
DISCUSSION
Based on previous randomised trials (Moertel et al, 1969;
Gastrointestinal Tumor Study Group, 1981; Gastrointestinal
Tumor Study Group, 1988), concurrent external-beam radio-
therapy and 5-FU have been generally accepted as the standard
treatment for locally advanced carcinomas. To intensify the
treatment efficacy, various anticancer agents and radiation
schedules are being investigated in clinical trials of chemora-
diotherapy (Roldan et al, 1988; Seydel et al, 1990; Wagener et al,
1996; Thomas et al, 1997; Prott et al, 1997; Okusaka et al, 2001).
However, marked improvement in their survival has not been
observed. In an attempt to optimise radiosensitisation, radio-
therapy with protracted 5-FU infusion has been examined recently,
but the median survival times were similar to those observed in
previous studies (Ishii et al, 1997).
Gemcitabine has been expected to be an agent that improves the
outcome of chemoradiotherapy for locally advanced pancreatic
cancer because it is a chemotherapeutic drug having meaningful
palliative and prognostic impact against advanced pancreatic
cancer, and it is also a potent radiosensitiser. Several experimental
studies have shown that more than one mechanism leads to the
potentiation of radiation-induced cell killing by gemcitabine
(Lawrence et al, 1996; Shewach and Lawrence, 1996; van Putten
et al, 2001). In clinics, various phase I studies for radiotherapy
with gemcitabine have been conducted (McGinn et al, 2001; Pipas
et al, 2001; Wolff et al, 2001; Ikeda et al, 2002; Poggi et al, 2002),
Table 2 Patterns of initial disease progression
Local No. (%)
Distant metastasis 33 (94)
Peritoneum 17 (49)
Liver 15 (43)
Lymph node 1 (3)
Ovary 1 (3)
Bone 1 (3)
Local and distant metastasis 1 (3)
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Figure 1 Progression-free survival and overall survival curves of patients
with locally advanced pancreatic cancer receiving radiotherapy with
gemcitabine.
Table 3 Acute toxicity
Grade 1 (%) 2 (%) 3 (%) 4 (%)
Haematological toxicity
Leucocytopenia 3 (7) 17 (40) 21 (50) 1 (2)
Neutropenia 9 (21) 15 (36) 11 (26) 3 (7)
Thrombcoytopenia 22 (52) 2 (5) 1 (2) 0 (0)
Anaemia 21 (50) 17 (40) 0 (0) 1
a (2)
Nonhaematological toxicity
Total bilirubin 10 (24) 5 (12) 1 (2) 0 (0)
AST 14 (33) 5 (12) 1 (2) 0 (0)
ALT 15 (36) 11 (26) 4 (10) 0 (0)
ALP 15 (36) 5 (12) 0 (0) 0 (0)
Creatinine 0 (0) 0 (0) 0 (0) 0 (0)
Anorexia 9 (21) 5 (12) 10 (24) 14 (33)
Nausea 11 (26) 11 (26) 9 (21) 0 (0)
Vomiting 10 (24) 7 (17) 0 (0) 0 (0)
Diarrhoea 1 (2) 1 (2) 0 (0) 0 (0)
Mucositis 0 (0) 0 (0) 0 (0) 0 (0)
Duodenal ulcer 0 (0) 0 (0) 0 (0) 1
a (2)
Fatigue 17 (40) 14 (33) 2 (5) 0 (0)
Skin rash 0 (0) 1 (2) 0 (0) 0 (0)
Infection 0 (0) 0 (0) 0 (0) 1
a (2)
AST¼aspartate aminotransferase; ALT¼alanine aminotransferase; ALP¼alkaline
phosphatase.
aOne patient died of duodenal bleeding and sepsis.
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lalthough the efficacy and safety of this combination have not been
fully elucidated in phase II trials. A phase I trial that was
conducted in our hospital determined the recommended dose of
weekly gemcitabine in the phase II chemoradiotherapy trial to be
250mgm
 2, because three of the six patients give a dose of
350mgm
 2 of gemcitabine demonstrated dose-limiting toxicities
involving neutropenia/leucopenia and elevated transaminase
(Ikeda et al, 2002).
The toxicity associated with radiotherapy with gemcitabine was
relatively severe in this phase II study. Grade 3–4 leucopenia and
neutropenia were observed in 52 and 33% of the patients,
respectively, although none of the patients showed neutropenic
fever. Nausea and anorexia were the most serious non-haemato-
logical toxicities in this treatment; 73% of the patients experienced
various degrees of nausea and 33% required intravenous
hyperalimentation. In all, 78% of the patients complained of
general fatigue and one patient (2%) refused continuation of the
treatment because of this adverse effect. These troublesome
toxicities observed in this study seem to be more frequent and
more severe compared with those in 5-FU-based chemoradiother-
apy (Ishii et al, 1997). There was one death attributed to duodenal
bleeding, which was arrested by transcatheter arterial embolisa-
tion, but deterioration of the general condition and lethal sepsis
were induced subsequently.
The present study, in which 42 patients with locally advanced
pancreatic cancer were treated with radiotherapy and weekly
gemcitabine, documented a marginal impact on patient survival;
the median survival time of 9.5 months is comparable to that in
patients receiving conventional chemotherapy using 5-FU. How-
ever, the incidence rate of distant metastasis at the time of disease
progression was remarkably higher with this treatment (97%) as
compared to that with 5-FU-based chemoradiotherapy, which was
reported to be 50% in our previous study (Ishii et al, 1997). This
suggests that gemcitabine at a dose of 250mgm
 2 is a potent
radiosensitiser for controlling local disease, but its ability as a
chemotherapeutic agent is insufficient to counteract systemic
tumour spread. To improve prognosis for these patients, future
investigations for treatment with more systemic effects are
warranted.
In an effort to increase capacity for systemic therapy, reduction
of the radiation field has been attempted. Investigators at the
University of Michigan elected to radiate the primary tumour
alone, without the inclusion of regional lymph nodes, and
administer full-dose gemcitabine concurrently, because the use
of full-dose gemcitabine requires reduction of the radiation dose,
based on their prior clinical experience (McGinn et al, 2001; Muler
et al, 2004). Reduction of the radiation field may be one of the
strategies not only for intense systemic therapy but also for
decreasing the troublesome gastrointestinal toxicity often observed
in our study; our recent retrospective study showed that a larger
planning target volume for irradiation was only a significant
predictor of severe acute intestinal toxicity in patients treated with
chemoradiotherapy using gemcitabine (Ito et al, 2003).
Crane et al (2002) retrospectively compared the toxicity and
efficacy of concurrent gemcitabine-based chemoradiation with
those of concurrent 5-FU-based chemoradiation in patients with
unresectable pancreatic cancer treated in the University of Texas
MD Anderson Cancer Center. In the study, there was a
significantly higher severe toxicity rate in patients treated with
gemcitabine than in those with 5-FU, although the median survival
times were similar between the two arms (gemcitabine vs 5-FU: 11
vs 9 months). They concluded that concurrent gemcitabine and
radiotherapy could be an extremely difficult combination to
administer safely, with a very narrow therapeutic index. Recently,
investigators in Taiwan reported favourable results for radio-
therapy with concurrent gemcitabine administration
(600mgm
2week
 1 for 6 weeks) in a small randomised study (Li
et al, 2003). The gemcitabine-based chemoradiotherapy showed a
significantly better median survival time (14.5 months) and a
comparable toxicity profile in comparison with the 5-FU-based
chemoradiotherapy (7.1 months). However, the number of
enrolled patients in this study was only 16–18 in each arm. The
results need further confirmation by larger multi-institutional
clinical trials.
In summary, the chemoradiotherapy used in this study has a
moderate activity against locally advanced pancreatic cancer and
an acceptable toxicity profile, but appears to have more frequent
acute toxicities compared with conventional chemoradiotherapy
using 5-FU. Most patients who underwent this therapy demon-
strated rapid appearance of distant metastasis. To explore
innovative approaches for locally advanced pancreatic cancer,
future investigations for treatment with more systemic effects and
less toxicity are needed.
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